HKHiroaki Kubota

Hiroaki Kubota

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroaki Kubota has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Age‐Associated Antimicrobial Resistance in Escherichia coli Isolates From Companion Dogs and Cats Linked to CTX‐M Gene Carriage

    by Kai Kobayashi, Hiroaki Kubota, Tsukasa Ariyoshi, Kohji Mori, Yoshitsugu Ochiai, Kenji Sadamasu, Takashi Chiba

    As companion animals live in close contact with humans, the presence of antimicrobial‐resistant organisms in these animals is an important issue in veterinary medicine from a One Health perspective. In this study, we isolated a total of 385 Escherichia coli strains from fecal samples collected from 218 companion dogs and 167 companion cats that visited veterinary clinics in Tokyo, Japan, from 2021 to 2024. Antimicrobial resistance to third‐generation cephalosporins and fluoroquinolones increased significantly with host age, even though fecal abnormalities were low relevance. A total of 60 isolates were resistant to at least one third‐generation cephalosporin, and whole‐genome analysis was performed to further characterize these isolates. The isolates were classified as CTX‐M gene‐carrying or AmpC‐associated isolates, including those carrying acquired AmpC genes and those harboring chromosomal ampC promoter mutations. The age‐associated increase was more pronounced among CTX‐M gene‐carrying isolates than among AmpC‐associated isolates. CTX‐M gene‐carrying isolates frequently exhibited concurrent levofloxacin resistance and were predominantly represented by ST131. Core‐genome multilocus sequence typing revealed that these CTX‐M gene‐carrying isolates were phylogenetically similar to previously reported isolates of both human and animal origin. These findings suggest that the age‐associated increase in resistance is related to the expansion of specific CTX‐M gene‐carrying lineages rather than to a uniform increase across all cephalosporin‐resistance mechanisms. Our results support the need for continuous investigation within a One Health framework and further epidemiological and genomic surveillance.

  • Open Access

    Multiple Mycoplasma Genitalium Genomic Lineages Carrying Resistance-Associated Mutations Among Men Who Have Sex With Men In Tokyo: A Prospective Cohort Study

    by Naokatsu Ando, Morika Mitobe, Yui Shintani, Misao Takano, Hiroaki Kubota, Kai Kobayashi, Hirofumi Miyake, Kohji Mori, Akira Kawashima, Haruka Uemura, et al.

    Background: Antimicrobial resistance in Mycoplasma genitalium is a public-health concern in the Western Pacific, but the genomic lineages in Japan are poorly characterised. We assessed whether predominant sequence types in two Tokyo outpatient cohorts represented one or multiple genomic backgrounds.Methods: We analysed pretreatment urine specimens and rectal swabs collected during 2019–24 using mgpB typing, Sanger sequencing of 23S rRNA, parC, and gyrA, and bacterial-load-selected target-enrichment whole-genome sequencing. Exploratory temporal comparisons used participant-clustered generalised estimating equations.Findings: Among 214 specimens from 207 participants, 160 typed specimens were included in the primary mgpB analysis. The two predominant mgpB sequence types (ST159 and ST143) accounted for 60·0% of typed specimens (37·5% and 22·5%, respectively). Macrolide resistance-associated mutations were detected in 151/167 (90·4%) evaluable specimens, parC substitutions at S83 or D87 in 119/148 (80·4%), and gyrA substitutions in 33/141 (23·4%). ST159 predominantly carried A2058T–S83I, whereas ST143 frequently carried A2059G–S83I–M95I. Of 76 selected specimens, 33 met the primary threshold of at least 93% genome-wide alignment. ST159-associated genomes formed a compact subclade, whereas ST143-associated genomes occupied a more heterogeneous group within clade B. Their separation was retained in an expanded sensitivity analysis of 37 genomes meeting at least 85% alignment.Interpretation: The two predominant sequence types, ST159 and ST143, occupied distinct genomic phylogenetic groups, consistent with the presence of more than one resistant genomic lineage in these cohorts. Combining targeted strain typing with selective whole-genome sequencing could strengthen sentinel surveillance.Funding: National Center for Global Health and Medicine (grant 24R001) and the Japan Agency for Medical Research and Development (26fk0410074h0002).

  • Open Access

    Three-day Doxycycline for Uncomplicated Chlamydia Trachomatis Infection in Men Who Have Sex With Men: A Single-arm, Open-label Study With a Contemporaneous 7-day Observational Cohort

    by Naokatsu Ando, Daisuke Mizushima, Yosuke Shimizu, Yukari Uemura, Kota Sawada, Misao Takano, Takahiro Aoki, Akira Kawashima, Ryo Kuwata, Hiroaki Kubota, et al.

    Background: Doxycycline for 7 days is standard treatment for uncomplicated Chlamydia trachomatis infection, but adherence can be suboptimal. We assessed a 3-day doxycycline regimen in men who have sex with men (MSM). Methods: In this open-label interventional study in Tokyo, adults aged 18 years or older with urogenital or extragenital C. trachomatis infection detected by nucleic acid amplification testing (NAAT) received doxycycline 100 mg twice daily for 3 days. Test-of-cure NAAT was scheduled at 2 and 4 weeks. The prespecified primary outcome was microbiological cure within 4 weeks. Outcomes from a non-randomised contemporaneous cohort receiving 7-day doxycycline were summarised. The trial was registered with the Japan Registry of Clinical Trials (jRCTs031240353). Findings: Between Nov 17, 2024, and Jan 13, 2026, 160 participants were enrolled in the 3-day study and 115 in the 7-day cohort. In the 3-day study, cure within 4 weeks occurred in 154 of 159 participants (96·9%, 95% CI 92·8–99·0), and mild adverse events occurred in 24 of 156 (15·4%). In the 7-day cohort, cure occurred in 111 of 113 participants (98·2%, 95% CI 93·8–99·8), and self-reported adverse events occurred in 17 of 78 (21·8%). Interpretation: A 3-day doxycycline regimen achieved high microbiological cure and was generally well tolerated in MSM with uncomplicated C. trachomatis infection. Because the 7-day cohort was not randomly assigned, randomised trials are needed before shortened therapy can be considered an alternative to standard treatment.

  • Plasmid-encoded FRI-10 carbapenemase harboured by non- Enterobacter species isolated from a wastewater sample in Tokyo, Japan

    by Kou Murakami, Miki Ida, Yasunori Suzuki, Makiko Kobayashi, Noriko Konishi, Rei Kato, Tsukasa Ariyoshi, Kai Kobayashi, Morika Mitobe, Hiroaki Kubota, et al.

  • Differential Copy Number of Chromosomal blaCTX−M−14 in Escherichia coli Sequence Type ST38 from Companion Dogs and Cats

    by Kai Kobayashi, Hiroaki Kubota, Tsukasa Ariyoshi, Yasunori Suzuki, Kohji Mori, Jun Suzuki, Yoshitsugu Ochiai, Kenji Sadamasu, Takashi Chiba


  • Open Access

    Evaluation of in vitro efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of Stenotrophomonas maltophilia

    by Wataru Aoki, Yoshifumi Uwamino, Hiroaki Kubota, Yuka Kamoshita, Rika Inose, Mika Nagata, Ho Namkoong, Hiromichi Matsushita

    We evaluated the in vitro activity of aztreonam-nacubactam (ATM-NAC) and cefepime-nacubactam (FEP-NAC) against 53 clinical isolates of Stenotrophomonas maltophilia from blood cultures. Minimum inhibitory concentrations (MICs) were determined via broth microdilution. While ATM-NAC showed more significant MIC reduction, FEP-NAC also remarkably decreased MICs, despite cefepime being a substrate for L1 β-lactamase. These findings suggest the potential of β-lactam–NAC combinations as promising alternatives, warranting further in vivo studies to confirm clinical applicability.


  • Open Access

    Cefiderocol susceptibility of Stenotrophomonas maltophilia species complex and carbapenem-resistant Pseudomonas aeruginosa isolates from blood cultures at a university hospital in Tokyo, Japan

    by Wataru Aoki, Yoshifumi Uwamino, Nagi Niida, Hiroaki Kubota, Yuka Kamoshita, Rika Inose, Mika Nagata, Osamu Ishihara, Shunsuke Uno, Ayumi Yoshifuji, et al.


  • Isolation of Rhodococcus equi bacteriophage ReT1 and investigation of its bactericidal effect

    by Toko Ishitsuka, Makoto Sugiyama, Hiroaki Kubota, Shinji Takai, Tsutomu Kakuda, Yasunori Suzuki


  • Open Access

    Multiplex amplicon sequencing for the comprehensive genotyping of Mycoplasma pneumoniae

    by Hiroaki Kubota, Rumi Okuno, Tsuyoshi Kenri, Yumi Uchitani, Tsukasa Ariyoshi, Isao Yoshida, Kai Kobayashi, Morika Mitobe, Jun Suzuki, Kenji Sadamasu

    Major genotyping methods used to characterize Mycoplasma pneumoniae strains are based on various experimental approaches that need to be implemented in parallel for each strain. In this study, we developed a comprehensive workflow based on amplicon sequencing using next-generation sequencing. This workflow comprised PCR amplification with seven tubes, collection into single tubes, shotgun sequencing, de novo assembly separating each target into individual contigs, and in silico genotyping. The results for p1 , orf6 , multilocus sequence types, 23S ribosomal RNA gene mutations conferring macrolide resistance, and single-nucleotide polymorphisms identifying the p1 type 1 lineage were obtained simultaneously. The genotyping accuracy was confirmed by comparing the sequences with the whole-genome sequences of 40 M . pneumoniae isolates collected in Tokyo, Japan. The workflow described not only enables high-throughput comprehensive data collection but also enables the detection of novel genotypes with single-nucleotide resolution. IMPORTANCE: Genotyping plays a central role in the molecular epidemiology of pathogenic bacteria, and many methods have been developed to identify prevalent lineages, infection routes, and antimicrobial resistance. Whole-genome sequencing generally provides most of the genetic information targeted by classic PCR-based schemes and has contributed to the construction of a simplified workflow for many bacterial species. However, several issues concerning the Mycoplasma pneumoniae genome, such as the presence of repetitive elements of the p1 gene, prevent the collection of genotyping results from a single run of short-read shotgun sequencing. Herein, we describe a simplified workflow using amplicon sequencing that covers most of the major genotyping schemes for M. pneumoniae , including p1 genotyping. The workflow effectively characterized M. pneumoniae clinical isolates. This workflow could help advance research on the molecular epidemiology of M. pneumoniae and the detection of novel genotypes.


  • Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium

    by Naokatsu Ando, Daisuke Mizushima, Misao Takano, Morika Mitobe, Kai Kobayashi, Hiroaki Kubota, Hirofumi Miyake, Jun Suzuki, Kenji Sadamasu, Takahiro Aoki, et al.

    Mycoplasma genitalium, which causes sexually transmitted diseases, is increasingly resistant to key antibiotics such as macrolides and quinolones, posing a challenge for treatment. To assess the effectiveness of prolonged sitafloxacin and doxycycline combination therapy as a new alternative treatment strategy for highly drug-resistant M. genitalium strains A prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan, from 1 January 2020 to 31 October 2022. Patients with M. genitalium urogenital or rectal infections and those who did not receive the initial sitafloxacin monotherapy were included. Patients were administered sitafloxacin and doxycycline for 21 days as salvage therapy. M. genitalium isolates were tested for parC, gyrA and 23S rRNA resistance-associated mutations. Twenty-seven patients received the combination therapy. All M. genitalium strains available for resistance analysis had parC (24/24) and macrolide resistance-associated (25/25) mutations, and 68% (17/25) had gyrA mutations. The overall cure rate was 77.8%. For strains with concurrent parC and gyrA mutations, the cure rate was 68.8% (P = 0.053) compared with that for monotherapy (37.5%). Prolonged combination therapy is highly effective against M. genitalium strains with concurrent parC and gyrA mutations. Future research should focus on establishing the optimal treatment duration and monitoring the risk of resistance.